WALTHAM, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Board has elected ...
Repligen Corp (NASDAQ:RGEN) released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents. The bioprocessing technology reported sales of ...
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of ...
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) in Q4 CY2024, but sales were flat year on year at $167.5 million. The company’s outlook for the full year was close to analysts’ ...
Repligen ((RGEN)) has held its Q3 earnings call. Read on for the main highlights of the call. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
Repligen Corporation (NASDAQ:RGEN), is not the largest company out there, but it saw a double-digit share price rise of over 10% in the past couple of months on the NASDAQGS. While good news for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results